Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3049% below fair value
$1.24−0.08 (-6.44%)
Close on Nov 17, 2026Market cap $5.68MP/E –Yield –
Earnings
Biomerica's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2022
$4.60M
EPS, Q2 FY2022
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Biomerica's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2022ended Nov 30, 2021 | Dec 16, 2021before the open | $4.60M | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Biomerica has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Biomerica puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Biomerica filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Results
See a number that looks wrong?